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In order to determine whether angiogenesis is a prognostic marker in lung cancer, we performed a systematic review of the
literature to assess the prognostic value on survival of microvessel count in patients with lung cancer. Published studies were
identiﬁed by an electronic search in order to aggregate survival results, after a methodological assessment using a quality scale
designed by the European Lung Cancer Working Party. To be eligible, a study had to deal with microvessel count assessment
in lung cancer patients on the primary site and to provide survival analysis according to microvessel count expression.
Microvessel count has been assessed on surgical samples by immunohistochemistry using factor VIII in 14 studies, CD34 in 10
and CD31 in eight. Respectively 1866, 1440 and 1093 non-small cell lung cancer patients were considered. The overall
median quality scores were respectively 52, 59 and 59% for studies assessing microvessel count via factor VIII, CD34 and
CD31, without signiﬁcant difference between studies evaluable or not for meta-analysis nor between studies with signiﬁcant or
non signiﬁcant results. Seven ‘factor VIII’ studies, nine ‘CD34’ and seven ‘CD31’ provided sufﬁcient data allowing a meta-
analysis on survival and were evaluable for results aggregation. This showed that a high microvessel count in the primitive lung
tumour was a statistically signiﬁcant poor prognostic factor for survival in non small cell lung cancer whatever it was assessed
by factor VIII (HR: 1.81; 95% CI: 1.16–2.84), CD34 (HR: 1.99; 95% CI: 1.53–2.58) or CD31 (HR: 1.80; 95% CI: 1.10–2.96).
Variations in survival among the individual studies can be explained in addition to patients selection criteria by the
heterogeneous methodologies used to stain and count microvessels: different antibody clones, identiﬁcation of ‘hotspots’,
Weidner or Chalkey counting method, cut-off selection. Microvessel count, reﬂecting the angiogenesis, appears to be a poor
prognostic factor for survival in surgically treated non small cell lung cancer but standardisation of angiogenesis assessment by
the microvessel count is necessary.
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Lung cancer is the most common cause of death by malignancy in
industrialised countries. Less than 15% of the patients will be cured
and enjoy long-term survival. This poor prognosis can be modu-
lated by characteristics related to the patient or the tumour.
These prognostic factors can be used for different purposes such
as a better understanding of the natural history of the disease or
the identiﬁcation of homogeneous patient’s populations with a
similar outcome proﬁle. Some independent clinical and biological
predictors have been identiﬁed for predicting survival (Paesmans
and Sculier, 1998): for resectable non small cell lung cancer
(NSCLC) age, performance status and TNM stage (Strauss,
1997). Among routine biological factors, serum lactate dehydrogen-
ase, white blood cell and neutrophil count have been shown to
signiﬁcantly predict survival in NSCLC (Kanters et al, 1995).
Recent developments in cytogenetic and molecular biology have
provided new ways to analyse prognosis. Biological substaging
using molecular markers in a risk stratiﬁcation strategy has been
proposed. Tumour suppressor genes, proto-oncogenes, markers
of proliferation and angiogenesis are some of the different research
tools.
Angiogenesis is the formation of new blood vessels from the
endothelium of the existing vasculature. These new capillaries arise
from pre-existing capillaries or venules and represent the conse-
quence of the growth of columns of aligned endothelial cells.
Adjacent columns contact to form loops, which then develop a
lumen. Neo-angiogenesis is fundamental in tumour growth,
progression and metastases and there is now experimental evidence
to indicate that tumour growth is dependent on angiogenesis
(Folkman, 1990). After a new tumour has attained a small size
of 1–2 mm, further growth and expansion of the tumour require
the induction of new blood vessels. Although this angiogenesis Received 25 April 2002; revised 19 July 2002; accepted 25 July 2002
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www.bjcancer.comalone is not sufﬁcient for developing metastases, new blood vessel
formation increases the opportunity for malignant cells to enter the
blood stream and thus the development of metastases (Weidner et
al, 1991). Newly formed capillaries are permeable because of frag-
mented basement membranes, making them more accessible to
errant tumour cells (Weidner et al, 1992).
Tumour angiogenesis is a complex multifactor process involving
growth factor and extracellular matrix enzymes. A variety of
proteins such as the vascular endothelial growth factor, the plate-
let-derived endothelial cell growth factors and the basic ﬁbroblast
growth factor released by tumour and stroma cells have been
recognised to be potent inducers of angiogenesis (Bikfalvi et al,
1997; Ishikawa et al, 1989; Ferrara, 2000).
Recent evidence suggests that tumour angiogenesis is associated
with patient outcome in a number of malignancies. Microvessel
density seems to be an important prognostic indicator in lung
cancer (Fontanini et al, 1995; Giatromanolaki et al, 1997) although
some studies have not found microvessel count to be predictive for
survival (Chandrachud et al, 1997; Pastorino et al, 1997).
Currently, different antibodies to three endothelial cell antigens
can be used to visualise the tumour blood vessels by immunohis-
tochemistry: factor VIII antigen or von Willebrand’s factor is
involved in platelet adhesion and aggregation; CD31 or PECAM
1 (platelet/endothelial cell adhesion molecule) is associated with
platelet adhesion in inﬂammation, wound healing, trans-endothe-
lial cell migration and cell migration; CD34 is involved in
leukocyte adhesion and endothelial cell migration during angiogen-
esis.
In order to determine whether microvessel count is a prognostic
factor for survival in lung cancer patients, we performed a systema-
tic review of the literature with methodological assessment.
MATERIALS AND METHODS
Publication selection
To be eligible for this review, trials had to deal with lung cancer
only, to evaluate the correlation between microvessel count and
survival, to measure the microvessel count in the primary tumour
(not in metastatic tissue or in tissue adjacent to the tumour) and
to be published as a full paper in the English or French language
literature. Abstracts were excluded from this analysis because of
insufﬁcient data to apply the scoring system and to evaluate the
methodological quality of the trial.
Articles were identiﬁed by an electronic search on Medline using
the keywords lung neoplasms, CD31, PECAM-1, CD34, factor VIII,
angiogenesis, neoangiogenesis, angiogenic factor, neovascularisa-
tion, microvessel, vessel density, vascular density or microvascular
density. The bibliographies reported in all the identiﬁed studies
were used for completion of the trials search. When authors
reported, in several publications, on the same patients populations,
only the most recent or complete study was included into the
analysis, in order to avoid overlapping between cohorts. The search
ended on September 2001.
Methodological assessment
In order to assess the methodology, each trial was read and scored
according to the ELCWP (European Lung Cancer Working Party)
scale by nine investigators (including six physicians, one patholo-
gist, one biologist and one biostatistician). Consensual agreement
on the scores attributed to each item for each trial was obtained
during meetings where the participation of many readers was a
guarantee for the correct interpretation of the articles. The scoring
system used in this literature review has already been described in
one of our prior systematic reviews (Steels et al, 2001). The overall
score assessed many dimensions of methodology, grouped in four
main categories: the scientiﬁc design, the description of the labora-
tory methods used to quantify MVC, the generalisability of the
results and the analysis of the study data. Each category had a
maximal score of 10 points with an overall maximal theoretical
score of 40 points. The ﬁnal scores were expressed as percentages,
higher values reﬂecting a better methodological quality. Studies
included in the systematic review were called ‘eligible’ and those
providing sufﬁcient data for the meta-analysis ‘evaluable’.
Statistical methods
A study was considered as signiﬁcant if the P value for the statis-
tical test comparing survival distributions between the groups with
and without high microvessel count was 50.05 in univariate analy-
sis. The study was called ‘positive’ when a high microvessel count
was identiﬁed as a signiﬁcant favourable prognostic factor for
survival. The study was called ‘negative’ if the same characteristic
was associated with a signiﬁcant detrimental effect on survival.
Finally, a study was called ‘not signiﬁcant’ if no statistical differ-
ence between the two groups was detected.
The association between two continuous variables was measured
by the Spearman ranks correlation coefﬁcient. Mann–Whitney test
was used to compare the distribution of the quality scores accord-
ing to the value of a binary variable.
If it was possible, we dichotomised the variable MVC by using
the observed median.
For the quantitative aggregation of survival results, we
measured the impact of microvessel count on survival by the
hazard ratio (HR) between the two survival distributions. For
each trial, this HR was estimated by a method depending on
the data provided in the publications. The most accurate method
consisted of calculating the estimated HR and its standard error
using two of the following parameters: the HR point estimate,
the logrank statistic or its P value, the O-E statistic (difference
between numbers of observed and expected events) or its
variance. If those data were not available, we looked for the total
number of events, the number of patients at risk in each group
and the logrank statistic or its P value allowing calculation of
an approximation of the HR estimate. Finally, if the only available
data were in the form of graphical representations of the survival
distributions, we extracted from them survival rates at some speci-
ﬁed times in order to reconstruct the HR estimate and its
variance, with the assumption that the rate of patients censored
was constant during the study follow-up (Parmar et al, 1998).
If this last method was used, three independent persons read
the curves to reduce the imprecision in the reading variations.
The individual HR estimates were combined into an overall HR
using Peto’s method (Yusuf et al, 1985), which consisted of using
a ﬁxed effect model assuming homogeneity of the individual true
HRs. This assumption was tested by performing w
2 tests for
heterogeneity. If the assumption of homogeneity had to be
rejected, we used a random-effects model as a second step. By
convention, an observed HR 41 implied a worse survival for
the group with a high microvessel count. This pejorative impact
of angiogenesis on survival was considered as statistically signiﬁ-
cant if the 95% conﬁdence interval for the overall HR did not
overlap 1.
RESULTS
Studies selection and characteristics
Twenty-one studies detecting MVC by factor VIII were selected.
Seven of the articles (Angeletti et al, 1996; Fontanini et al,
1996, 1997b, 1998a; Harpole et al, 1996; Takanami et al,
1999; D’Amico et al, 2000) were excluded because identical
cohorts of patients were included in other selected publications.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 694–701In the 14 remaining eligible studies (Macchiarini et al, 1994;
Yamazaki et al, 1994; Fontanini et al, 1995; Mattern et al,
1995; Chandrachud et al, 1997; Giatromanolaki et al, 1997;
Takanami et al, 1997; Duarte et al, 1998; Imoto et al, 1998;
Aikawa et al, 1999; D’Amico et al, 1999; Ohta et al, 1999;
Sheng et al, 2000; Yano et al, 2000), published between 1994
and 2000, the total number of patients was 1866 ranging from
28 to 408. The main characteristics of these 14 studies are
shown in Table 1. Twelve of them dealt with NSCLC whatever
the histologic subtype considered and two with adenocarcinoma
only. Ten studies concerned only limited disease and four all
stages (I to IV). Different antibodies were used to assess factor
VIII positivity.
CD34 was used in 13 studies. Three of the articles (Lucchi et al,
1997; Fontanini et al, 1998b; Cox et al, 2000) were excluded
because identical cohorts of patients were included in other publi-
cations. In the 10 remaining eligible studies (Fontanini et al, 1997a;
Matsuyama et al, 1998; Shibusa et al, 1998; Dazzi et al, 1999; Cagi-
ni et al, 2000; Takanami et al, 2000; Yano et al, 2000; Cox et al,
2001; Liao et al, 2001; Offersen et al, 2001), published between
1997 and 2001, the total number of included patients was 1440
ranging from 44 to 407 patients by trial. The main characteristics
of these 10 eligible studies are shown in Table 2. Eight of them
dealt with NSCLC whatever the histologic subtype considered
and two with adenocarcinoma only. Nine studies concerned only
limited stage disease and one, all stages. Most of the time, clone
QB-END 10 monoclonal antibody was used to assess CD 34
immunoreactivity.
In terms of CD31 detection, 18 studies were selected. Ten were
excluded (Giatromanolaki et al, 1996a,b, 1997, 2000a,b; Koukour-
akis et al, 1997, 1999, 2000a,b; Kakolyris et al, 1999) because
identical cohorts of patients were used in other selected publica-
tions. In the eight remaining eligible studies (Apolinario et al,
1997; Kawaguchi et al, 1997; Pastorino et al, 1997; Duarte et al,
1998; Ohta et al, 1999; O’Byrne et al, 2000; Han et al, 2001; Hase-
gawa et al, 2001), published between 1996 and 2001, the total
Table 1 Main characteristics and results of the eligible studies evaluating the microvessel count by factor VIII
Author Year Histology Stage n HR estimation Results Cut-off Antibody
Yamazaki et al 1994 Adenoc I-IV 42 No data NS Arbitrary Dako Po Ab
Macchiarini et al 1994 NSCLC I-III 28 No data Negative Median Dako Mo Ab
Fontanini et al 1995 NSCLC I-IIIB 248 Survival curves Negative Median Dako
Mattern et al 1995 NSCLC I-III 204 Survival curves NS Mean Dako
Takanami et al 1997 Adenoc I-IV 120 Survival curves Negative Arbitrary Nichirei Mo Ab
Chandrachud et al 1997 NSCLC I-IIIA 88 Logrank NS Median Dako A0082
Giatromanolaki et al 1997 NSCLC I-II 134 No data Negative Arbitrary Dako Mo F8/86
Duarte et al 1998 NSCLC I 96 Survival curves Negative Mean Ventana Mo Ab
Imoto et al 1998 NSCLC I-IIIB 91 HR+CI NS Mean Dako Po A0082
D’Amico et al 1999 NSCLC I 408 Logrank Negative Arbitrary Biogenex Mo Ab
Aikawa et al 1999 NSCLC I-IIIB 97 No data Negative Arbitrary TaKaRa Mo Ab
Ohta et al 1999 NSCLC I 104 No data Negative Mean Dako Po Ab
Yano et al 2000 NSCLC I-IV 108 No data NS Median Dako Mo Ab
Sheng et al 2000 NSCLC I-IV 98 No data NC Median Santa Cruz
NSCLC=non-small cell lung cancer; n=number of patients; HR+CI=hazard ratio+conﬁdence interval; Results=author’s results; Adenoc=adenocarcinoma; Cut-off=cut-off for
positivity; NS=not signiﬁcant; NC=not conclusive; Mo Ab=monoclonal antibody; Po Ab=polyclonal antibody. These abbreviations also apply to Tables 2 and 3.
Table 2 Main characteristics and results of the eligible studies evaluating the microvessel count by CD34
Author Year Histology Stage n HR estimation Results Cut-off Antibody
Fontanini et al 1997a NSCLC I-III 407 Logrank Negative Median Clone QB END 10
Shibusa et al 1998 Adenoc I 44 Survival curves Negative Mean Clone QB END 10
Matsuyama et al 1998 NSCLC I-IIIB 101 Logrank Negative Mean Clone QB END 10
Dazzi et al 1999 NSCLC I-IIIB 76 Logrank NS Median Clone QB END 10
Cagini et al 2000 NSCLC I-IIB 99 Logrank NS Median Clone QB END 10
Takanami et al 2000 Adenoc I-IIIA 180 Survival curves Negative Mean Novocastra Mo Ab
Yano et al 2000 NSCLC I-IV 108 Logrank Negative Median Clone QB END 10
Liao et al 2001 NSCLC I-III 115 No data NS Arbitrary No data
Offersen et al 2001 NSCLC I-III 143 Survival curves NS Median Clone QB END 10
Cox et al 2001 NSCLC I-IIIA 167 HR+CI Negative Median Clone QB END 10
Table 3 Main characteristics and results of the eligible studies evaluating the microvessel count by CD31
Author Year Histology Stage n HR estimation Results Cut-off Antibody
Ohta et al 1999 NSCLC I 15 Logrank Negative Mean Dako Mo Ab
Kawagushi et al 1997 Adenoc I 42 Survival curves Negative Median Clone JC70
Apolinario et al 1997 NSCLC I-IIIA 104 Survival curves Negative Median Clone JC70
Pastorino et al 1997 NSCLC I 515 HR+CI NS Median Clone JC70
Duarte et al 1998 NSCLC I 96 Survival curves NS Median Dako Mo Ab
O’Byrne et al 2000 NSCLC IIIA 183 Survival curves Negative Arbitrary Clone JC70
Han et al 2001 NSCLC I 85 Survival curves Negative Arbitrary Ventana
Hasegawa et al 2001 NSCLC I-III 53 No data NS Mean Clone JC70
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British Journal of Cancer (2002) 87(7), 694–701 ã 2002 Cancer Research UKnumber of included patients was 1093 ranging from 15 to 515
patients by trial. The main characteristics of the eight studies eligi-
ble for the systematic review are shown in Table 3. Seven of them
dealt with NSCLC whatever the histologic subtype and one with
adenocarcinoma only. Seven studies concerned only limited stage
disease and one all stages diseases. In ﬁve studies, JC70 monoclonal
antibody was used to detect CD31.
For the three antibodies, immunoreactivity was always assessed
on surgical samples.
Studies results reports
When factor VIII was used to assess MVC, eight studies reported
‘negative’ results, ﬁve were not signiﬁcant and one was not conclu-
sive. Seven studies were evaluable for meta-analysis.
Looking at the survival results in the studies dealing with CD34,
six studies were ‘negative’ and four were not signiﬁcant. Nine
studies were evaluable for meta-analysis.
When CD31 was detected, ﬁve studies were ‘negative’ and three
not signiﬁcant. Seven were evaluable for meta-analysis.
Quality assessment
Concerning ‘factor VIII’ studies, the overall quality score ranged
from 36.2% to 72.9% with a median of 52.4%. The ‘design’
subscore had the lowest value (median: 30%). There was no statis-
tically signiﬁcant quality difference between evaluable and non-
evaluable studies for meta-analysis (median overall scores: 68.1%
vs 49.6%, P=0.07). No statistically signiﬁcant quality difference
was shown between signiﬁcant and non-signiﬁcant trials (median
overall scores 49.7% vs 56.9%, P=0.73).
For ‘CD34’ studies, the overall quality score ranged from
43.3% to 76.3% with a median of 59.3%. The ‘design’ subscore
had the lowest median value (40%). No statistically signiﬁcant
quality difference was shown between the signiﬁcant and the
non-signiﬁcant trials (median overall scores 63.6% vs 59.2%,
P=0.67).
For ‘CD31’ studies, the overall quality score ranged from
38.9% to 72.9% with a median of 59.5%. The ‘design’ subscore
had the lowest median value (45%). No statistically signiﬁcant
quality difference was shown between the signiﬁcant and the
non-signiﬁcant trials (median overall scores 53.2% vs 69.9%,
P=0.17).
There was no signiﬁcant correlation between quality scores and
the number of patients included in the studies or with the date of
publication of the studies.
Meta-analysis
The absence of signiﬁcant quality difference between signiﬁcant
and non-signiﬁcant studies allowed us to perform a quantitative
aggregation of the survival results.
Among the 32 trials eligible for the systematic review evaluating
MVC with factor VIII, nine could not be included in the meta-
analysis due to insufﬁcient data to estimate the HR or because data
concerned only some subgroups of patients. The hazard ratios of
the 23 evaluable studies were calculated by one of the three meth-
ods reported in the Materials and methods section. Hazard ratio
and 95% conﬁdence intervals were published in three trials. They
were approximated from the logrank statistic and the number of
events in eight studies. Finally, the HR and its variability had to
be extrapolated from the graphical representations of the survival
distributions in the 12 others. With a ﬁxed-effect model, the HR
was 1.71 (95% CI: 1.44–2.04) for factor VIII studies, 1.95 (95%
CI: 1.65–2.30) for CD34 studies and 1.40 (95% CI: 1.17–1.63)
for CD31 studies. However, the test of heterogeneity was signiﬁcant
for factor VIII (P50.001), CD34 (P=0.02) and CD31 studies
(P=0.004). Thus, we calculated the HR using a random-effects
model and obtained a value which was statistically signiﬁcant for
factor VIII HR: 1.81 (95% CI: 1.16–2.84) (Figure 1), for CD34
1.99 (95% CI: 1.53–2.58) (Figure 2) and for CD31 HR: 1.80
(95% CI: 1.10–2.96) (Figure 3).
DISCUSSION
In this systematic review, by pooling all the studies comparing
survival of lung cancer patients according to the angiogenic
activity of the tumour, as expressed by the MVC, we show that
a high MVC is a poor prognosis factor for survival in surgical
NSCLC whatever the antibody used for assessment of the vessel
count. This observation is potentially important for prognostic
reasons and treatment purposes. Angiogenesis assessment might
be useful not only in stratifying patients for different (adjuvant)
treatment regimens but also in predicting their response to
chemotherapy (Koukourakis, 2001; Mattern, 2001), to anti-angio-
genic therapies and identifying the precancerous lesions (Pazouki
et al, 1997).
Chandrachud et al, 1997
D'Amico et al, 1999
Duarte et al, 1998
Fontanini et al, 1995
Imoto et al, 1998
Mattern et al, 1995
Takanami et al, 1997
0.0 2.5 5.0 7.5 10.0
HR: 1.81; 95% CI: 1.16–2.84
Figure 1 Results of the meta-analysis of the studies using factor VIII. HR41 implies a survival disadvantage for the group with a high microvessel count.
The square size is proportional to the number of patients included in the study. The centre of the lozenge gives the combined HR for the meta-analysis and
its extremities the 95% conﬁdence interval.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 694–701It is also to be noted that the trials published on the topic
concerned NSCLC treated, at least, by surgery; we could thus not
extrapolate our results to metastatic NSCLC or small cell lung
cancer.
To perform the meta-analysis, we have used a methodology
similar to previous systematic reviews of our group on the treat-
ment of lung cancer (Meert et al, 1999) but adapted to the ﬁeld
of biological prognostic factors (Steels et al, 2001). The absence
of statistically signiﬁcant difference in quality score between signif-
icant and non-signiﬁcant publications allowed us to perform a
quantitative aggregation of the individual trials results.
Our approach does not however prevent all potential biases. We
restricted our review to articles published in French or English
language because other languages such as Japanese were not acces-
sible to the readers. This selection could favour the positive studies
that are more often published in English while the negative ones
tend to be more often reported in native languages (Egger et al,
1997). Another possible source of confusion is the use of a same
cohort of patients in different publications. It might be difﬁcult
to avoid the same patients being included more than once in the
meta-analysis. We have excluded publications where it seemed to
be the case after writing to some of the authors in order to have
more information on patients’ cohort, a procedure that was unsuc-
cessful: we had only one partial response. Harris conﬁrmed that
there were an overlapping of the same patients in the series of
Giatromanolaki, Koukourakis et al The method of extrapolation
of HRs also needs to be discussed. When HRs were not reported
by the authors, they were calculated from the data reported in
the article and, if not available, extrapolated from the survival
curves, implying assumptions on the censoring process. This
approach might also have been associated with errors due to
imprecision in the reading, although three independent persons
read the curves to reduce the reading variation.
Our review took into account only fully published studies. We
did not look for unpublished trials and abstracts because our
methodology required data available in full publications only.
Meta-analysis based on individual data is considered by some
authors as a gold standard (Stewart and Parmar, 1993). Systematic
reviews of the literature should not be confused with meta-analyses
of individual patient data. The ﬁrst approach is based on fully
published studies and provides an exhaustive and critical analysis
on the topic with an adequate methodology based on the criteria
of Mulrow (1987). The second approach is, in fact, a new study
taking into account all performed studies on the topic, published
or not, requiring individual data update by the investigators and
is much more time-consuming. Nevertheless, as shown by our
Apolinario et al, 1997
Duarte et al, 1998
Han et al, 2001
Kawaguchi et al, 1997
O'Byrne et al, 2000
Ohta et al, 1999
Pastorino et al, 1997
0.0 2.5 5.0 7.5 10.0
HR: 1.80; 95% CI: 1.10–2.96
Figure 3 Results of the meta-analysis of the studies using CD31.
Cagini et al, 2000
Cox et al, 2001
Dazzi et al, 1999
Fontanini et al, 1997a, b
Matsuyama et al, 1998
Offersen et al, 2001
Shibusa et al, 1998
Takanami et al, 2000
Yano et al, 2000
0.0 2.5 5.0 7.5 10.0
HR: 1.99; 95% CI: 1.53–2.58
Figure 2 Results of the meta-analysis of the studies using CD34.
Microvessel density and lung cancer
A-P Meert et al
698
British Journal of Cancer (2002) 87(7), 694–701 ã 2002 Cancer Research UKmeta-analysis on the role of prophylactic cerebral irradiation in
small-cell lung cancer (Meert et al, 2001), based on published data,
we obtained the same results as in the meta-analysis based on indi-
vidual data (Auperin et al, 1999).
Variations in survival results among the studies could be
explained by the heterogeneity in methodologies used to stain
and count microvessels in the tumours in addition to variation
in patients population. The estimated vascularity in tissues
sections can be signiﬁcantly affected by variations in the applied
methodology including pre-treatment and antibody use. The
vessels in tumour samples can be identiﬁed by some different
endothelial cell-speciﬁc antibodies: most often recognising factor
VIII, CD31 or CD34 related antigen. Factor VIII (Von Willeb-
rand’s factor) was one of the ﬁrst marker used for staining
microvessels but it may be imprecise to quantify microvascula-
ture for various reasons. Firstly, factor VIII is not expressed
in all endothelial cells. The microvessels endothelial cells are less
rich in Weibel-Palade bodies, which store factor VIII, than the
endothelial cells of macrovessels (and the endothelial cells of
neocapillaries may be activated by cytokines releasing their
factor VIII stores). Secondly, factor VIII is also present in
lymphatic endothelium and in platelets leading to a cross-reac-
tivity with megakaryocytes, platelets and lymphatic endothelial
cells. CD34, a heavily glycosylated transmembrane protein, is
expressed on immature human haematopoietic precursor cells
and is progressively lost during maturation. It is also present
in the luminal endothelial membrane. CD34 is more sensitive
and speciﬁc than factor VIII for staining endothelial cells
induced by tumour neovascularisation (Tanigawa et al, 1996)
but could also stain some lymphatic vessels. Only speciﬁc anti-
bodies (i.e. LYVE 1, VEGF-C) can be used to detect lymphatics
and not blood vessels. Anti-CD34 antibody seems to be more
reliable in terms of speciﬁcity and reproducibility than monoclo-
nal antibodies generated against other endothelial cell antigens
(Tanigawa et al, 1996). In invasive breast cancer, CD34 has
been shown to yield higher microvessel values than CD31 or
factor VIII (Martin et al, 1997) and does not stain any tumour
or inﬂammatory cells as CD31 or factor VIII. CD31 is a trans-
membrane glycoprotein highly expressed in mature and
immature endothelium and its localisation at the endothelial cell
junctions suggests an important role in transendothelial migra-
tion. CD31 is expressed during myelomonocytic cellular
differentiation and consequently may cross-react with plasma
cells, platelets, neutrophils, peripheral T cells and mantle zone
B cells; endothelial staining can be easily differentiated on the
basis of the morphological differences. JC70 antibody stains also
CD31 positive lymphocytes that could be a prognostically
important inﬂammatory component in lung cancer (Giatroma-
nolaki et al, 1997). For some authors, CD31 seems to be the
most sensitive marker for the endothelial cells and consistently
stains more vessels than did factor VIII (Horak et al, 1992).
An international consensus on the methodology and criteria of
evaluation of microvessel density proposed that anti-CD31
monoclonal antibody should be the standard for microvessel
assessment (Vermeulen et al, 1996) as it is superior on parafﬁn
sections. But as CD34 has been shown to yield higher microves-
sel values than CD31 or factor VIII in breast cancer (Martin et
al, 1997), it might be useful to combine CD34 and CD31 anti-
bodies. In lung cancer, Offersen et al (2001) compared the
staining with these three antibodies. He found that CD34
showed the best labelling of the endothelial cells and no back-
ground staining (data not shown). Yano et al (2000) found that
correlation between factor VIII and CD34 staining for MVC was
not strong and that staining for CD 34 signiﬁcantly correlated
with survival in adenocarcinoma but staining for factor VIII
did not. Duarte et al (1998) reported that CD 31 did not
predict survival in stage I NSCLC and did not correlate strongly
with factor VIII which is correlated with lung cancer death.
Giatromanolaki et al (1997) concluded that CD31 is sensitive
for highlighting small, immature microvessels and is better
correlated with nodal involvement and overall survival than
factor VIII. Unfortunately, data were not sufﬁcient to compare
the three antibodies by a meta-analysis methodology.
Contradictory results in the literature may also be explained by
variations in vascularity between areas in different sections from
the same block or among blocks taken from the same tumour
(de Jong et al, 1995) and by the methods used to measure vascu-
larity (Pazouki et al, 1997). In large tumours, it could be necessary
to examine multiple blocks in order to determine the overall vascu-
larity of the tumour. Identifying the area of maximal microvessel
density seems to be an important step in the counting method
(Vermeulen et al, 1997) as tumour dissemination is more likely
to occur at sites of high microvessel density. In lung cancer, the
border between malignant and benign tissues is often blurred by
atelectases, ﬁbrosis and inﬂammatory cells, making the problem
more difﬁcult. The difﬁculty in recognising the vascular ‘hotspots’
may account for studies that failed to ﬁnd an association between
MVC and poor patients survival.
The technique used to count the microvessels is also different
among the articles. Most of the studies used a technique similar
to that proposed by Weidner et al (1991). The areas of highest
neovascularization (‘hotspots’) is found by scanning the tumour
sections at low power (406 and 1006) and then individual
microvessels are counted on a 2006 and 4006 ﬁeld. Each count
is expressed as the highest number of microvessels identiﬁed within
any 2006 or 4006 ﬁeld. This technique is slow and laborious. A
eye piece graticule (as a 25-point Chalkey graticule) has also been
applied for vascular scoring in patients with NSCLC (Giatromano-
laki et al, 1996a). In breast cancer, Fox et al (1995) showed that
Chalkey counting is a rapid and objective method of quantifying
tumour angiogenesis and gives independent prognostic informa-
tion. A proposition of consensus identiﬁed the Chalkey method
as slightly more objective (Vermeulen et al, 1996). We did not
perform aggregation of the results in term of microvessel counting
technique because the techniques were too heterogeneous.
Moreover, there is no standardised cut-off used for stratifying
patients into high and low vascular groups. Some authors used
the MVC median or the MVC mean and others the ‘best cut-
off’, which is often arbitrary deﬁned or chosen using multiple tests
with a corresponding increase in the probability of founding a false
positive results. The selection of the median value of the expression
levels is a standard approach to analyse new prognostic factors,
even if it may lead to some loss of information.
Assessment of tumour vascularity by immunohistochemistry on
parafﬁn-embedded tissues can be easily performed in laboratory
but standardisation of angiogenesis quantiﬁcation is necessary in
order to better deﬁne its prognostic value (Vermeulen et al,
1996) and to facilitate a routine use.
In conclusion, a high MVC, reﬂecting tumour neoangiogenesis,
is a poor survival prognostic factor for NSCLC surgically treated
patients. These results were based on an aggregation of data
obtained by univariate survival analysis in retrospective trials. In
order to become an useful prognostic factor, a standardisation of
angiogenesis quantiﬁcation is necessary and the present results
need to be conﬁrmed by an adequately designed prospective study
with an appropriate multivariate analysis taking into account the
classical well deﬁned prognostic factors for lung cancer.
ACKNOWLEDGEMENTS
This research was supported by the ‘FNRS’ and by ‘Les Amis de
l’Institut Bordet’. A-P Meert is a Research Fellow FNRS.
Microvessel density and lung cancer
A-P Meert et al
699
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 694–701REFERENCES
Aikawa H, Takahashi S, Fujimura S, Sato M, Endo C, Sakurada A, Kondo T,
Tanita T, Matsumura Y, Ono S, Saito Y, Sagawa M (1999) Immunohisto-
chemical study on tumor angiogenic factors in non-small cell lung cancer.
Anticancer Res 19: 4305–4310
Angeletti CA, Lucchi M, Fontanini G, Mussi A, Chella A, Ribechini A, Vignati
S, Bevilacqua G (1996) Prognostic signiﬁcance of tumoral angiogenesis in
completely resected late stage lung carcinoma (stage IIIA-N2). Cancer 78:
409–415
Apolinario RM, van der Valk P, de Jong JS, Deville W, Ark-Otte J, Dingemans
AM, van Mourik JC, Postmus PE, Pinedo HM, Giaccone G (1997) Prog-
nostic value of the expression of p53, bcl-2, and bax oncoproteins, and
neovascularization in patients with radically resected non-small-cell lung
cancer. J Clin Oncol 15: 2456–2466
Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ,
Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J (1999) Prophy-
lactic cranial irradiation for patients with small-cell lung cancer in
complete remission. Prophylactic Cranial Irradiation Overview Collabora-
tive Group. N Engl J Med 341: 476–484
Bikfalvi A, Klein S, Pintucci G, Rifkin DB (1997) Biological roles of ﬁbroblast
growth factor-2. Endocr Rev 18: 26–45
Cagini L, Monacelli M, Giustozzi G, Moggi L, Bellezza G, Sidoni A, Bucciar-
elli E, Darwish S, Ludovini V, Pistola L, Gregorc V, Tonato M (2000)
Biological prognostic factors for early stage completely resected non- small
cell lung cancer. J Surg Oncol 74: 53–60
Chandrachud LM, Pendleton N, Chisholm DM, Horan MA, Schor AM
(1997) Relationship between vascularity, age and survival in non-small-cell
lung cancer. Br J Cancer 76: 1367–1375
Cox G, Jones JL, Andi A, Waller DA, O’Byrne KJ (2001) A biological staging
model for operable non-small cell lung cancer. Thorax 56: 561–566
Cox G, Walker RA, Andi A, Steward WP, O’Byrne KJ (2000) Prognostic
signiﬁcance of platelet and microvessel counts in operable non-small cell
lung cancer. Lung Cancer 29: 169–177
D’Amico TA, Aloia TA, Moore MB, Herndon JE, Brooks KR, Lau CL,
Harpole Jr DH (2000) Molecular biologic substaging of stage I lung cancer
according to gender and histology. Ann Thorac Surg 69: 882–886
D’Amico TA, Massey M, Herndon JE, Moore M-B, Harpole DH (1999) A
biologic risk model for stage I lung cancer: immunohistochemical analysis
of 408 patients with the use of ten molecular markers. J Thor Cardiovasc
Surg 117: 736–743
Dazzi C, Cariello A, Maioli P, Solaini L, Scarpi E, Rosti G, Lanzanova G,
Marangolo M (1999) Prognostic and predictive value of intratumoral
microvessels density in operable non-small-cell lung cancer. Lung Cancer
24: 81–88
de Jong JS, van Diest PJ, Baak JP (1995) Heterogeneity and reproducibility of
microvessel counts in breast cancer. Lab Invest 73: 922–926
Duarte IG, Bufkin BL, Pennington MF, Gal AA, Cohen C, Kosinski AS,
Mansour KA, Miller JI (1998) Angiogenesis as a predictor of survival after
surgical resection for stage I non-small-cell lung cancer. J Thor Cardiovasc
Surg 115: 652–659
Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G
(1997) Language bias in randomised controlled trials published in English
and German. Lancet 350: 326–329
Ferrara N (2000) VEGF: an update on biological and therapeutic aspects.
Curr Opin Biotechnol 11: 617–624
Folkman J (1990) What is the evidence that tumors are angiogenesis depen-
dent? J Natl Cancer Inst 82: 4–6
Fontanini G, Bigini D, Vignati S, Basolo F, Mussi A, Lucchi M, Chine ` S,
Angeletti CA, Harris AL, Bevilacqua G (1995) Microvessel count Predicts
metastatic disease and survival in non-small cell lung cancer. J Pathol
117: 57–63
Fontanini G, Boldrini L, Vignati S, Chine ` S, Basolo F, Silvestri V, Lucchi M,
Mussi A, Angeletti CA, Bevilacqua G (1998a) Bcl2 and p53 Regulate
Vascular Endothelial growth Factor (VEGF)-mediated Angiogenesis in
Non-small Cell Lung Carcinoma. Eur J Cancer 34: 718–723
Fontanini G, De Laurentis M, Vignati S, Chine ` S, Lucchi M, Silvestri V, Mussi
A, De Placido S, Tortora P, Raffaele Bianco A, Gullick W, Angeletti CA,
Bevilacqua G, Ciardello F (1998b) Evaluation of epidermal growth
factor-related growth factors and receptors and of neoangiogenesis in
completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin
and microvessel count are independent prognostic indicators of survival.
Clin Cancer Res 4: 241–249
Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardello F, De Laurentis M, De
Placido S, Basolo F, Angeletti CA, Bevilacqua G (1997a) Angiogenesis as a
prognostic indicator of survival in non-small-cell lung carcinoma: a
prospective study. J Natl Cancer Inst 89: 881–886
Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Chine ` S, Angeletti CA,
Bevilacqua G (1996) Recurrence and death in non-small cell lung carcino-
mas: a prognostic model using pathological parameters, microvessel count,
and gene protein products. Clin Cancer Res 2: 1067–1075
Fontanini G, Vignati S, Lucchi M, Mussi A, Calcinai A, Boldrini L, Chine ` S,
Silvestri V, Angeletti CA, Basolo F, Bevilacqua G (1997b) Neoangiogenesis
and p53 protein in lung cancer: their prognostic role and their relation
with vascular endothelial growth factor (VEGF) expression. Br J Cancer
75: 1295–1301
Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL (1995)
Quantitation and prognostic value of breast cancer angiogenesis: compar-
ison of microvessel density, Chalkley count, and computer image analysis.
J Pathol 177: 275–283
Giatromanolaki A, Koukourakis MI, O’Byrne KJ, Fox S, Whitehouse RM,
Talbot DC, Harris AL, Gatter KC (1996a) Prognostic value of angiogenesis
in operable non-small cell lung cancer. J Pathol 179: 80–88
Giatromanolaki A, Koukourakis MI, O’Byrne KJ, Kaklamanis L, Dicoglou C,
Trichia E, Whitehouse RM, Harris AL, Gatter KC (1996b) Non-small cell
lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and
poor prognosis. Anticancer Res 16: 3819–3826
Giatromanolaki A, Koukourakis MI, Sivridis E, O’Byrne K, Cox G, Thorpe
PE, Gatter KC, Harris AL (2000a) Coexpression of MUC1 glycoprotein
with multiple angiogenic factors in non-small cell lung cancer suggests
coactivation of angiogenic and migration pathways. Clin Cancer Res 6:
1917–1921
Giatromanolaki A, Koukourakis MI, Sivridis E, O’Byrne K, Gatter KC, Harris
AL (2000b) ‘Invading edge vs. inner’ (edvin) patterns of vascularization: an
interplay between angiogenic and vascular survival factors deﬁnes the clin-
ical behaviour of non-small cell lung cancer. J Pathol 192: 140–149
Giatromanolaki A, Koukourakis MI, Theodossiou D, Barbatis K, O’Byrne K,
Harris AL, Gatter KC (1997) Comparative evaluation of angiogenesis
assessment with anti-factor-VIII and anti-CD31 immunostaining in non-
small cell lung cancer. Clin Cancer Res 3: 2485–2492
Han H, Silverman JF, Santucci TS, Macherey RS, d’Amato TA, Tung MY,
Weyant RJ, Landreneau RJ (2001) Vascular endothelial growth factor
expression in stage I non-small cell lung cancer correlates with neoangio-
genesis and a poor prognosis. Ann Surg Oncol 8: 72–79
Harpole DH, Richards WG, Herndon JE, Sugarbaker DJ (1996) Angiogenesis
and molecular biologic substaging in patients with stage I non-small cell
lung cancer. Ann Thorac Surg 61: 1470–1476
Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K
(2001) Transforming growth factor-beta1 level correlates with angiogen-
esis, tumor progression, and prognosis in patients with nonsmall cell
lung carcinoma. Cancer 91: 964–971
Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Step-
niewska K, Harris AL (1992) Angiogenesis, assessed by platelet/endothelial
cell adhesion molecule antibodies, as indicator of node metastases and
survival in breast cancer. Lancet 340: 1120–1124
Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K (1998)
Vascular endothelial growth factor expression in non-small-cell lung
cancer: prognostic signiﬁcance in squamous cell carcinoma. J Thor Cardi-
ovasc Surg 115: 1007–1014
Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K,
Usuki K, Takaku F, Risau W, Heldin CH (1989) Identiﬁcation of angio-
genic activity and the cloning and expression of platelet-derived
endothelial cell growth factor. Nature 338: 557–562
Kakolyris S, Giatromanolaki A, Koukourakis MI, Leigh IM, Georgoulias V,
Kanavaros P, Sivridis E, Gatter KC, Harris AL (1999) Assessment of vascu-
lar maturation in non-small cell lung cancer using a novel basement
membrane component, LH39: correlation with p53 and angiogenic factor
expression. Cancer Res 59: 5602–5607
Kanters SD, Lammers JW, Voest EE (1995) Molecular and biological factors
in the prognosis of non-small cell lung cancer. Eur Respir J 8: 1389–1397
Kawaguchi T, Yamamoto S, Kudoh S, Goto K, Wakasa K, Sakurai M (1997)
Tumor angiogenesis as a major prognostic factor in stage I lung adenocar-
cinoma. Anticancer Res 17: 3743–3746
Microvessel density and lung cancer
A-P Meert et al
700
British Journal of Cancer (2002) 87(7), 694–701 ã 2002 Cancer Research UKKoukourakis MI (2001) Tumour angiogenesis and response to radiotherapy.
Anticancer Res 21(6B): 4285–4300
Koukourakis MI, Giatromanolaki A, Guddo F, Kaklamanis L, Vignola M,
Kakolyris S, Turley H, Georgoulias V, Bonsignore G, Gatter KC, Harris
AL (2000a) c-erbB-2 and episialin challenges host immune response by
HLA class I expression in human non-small-cell lung cancer. J Immunother
23: 104–114
Koukourakis MI, Giatromanolaki A, O’Byrne KJ, Cox J, Krammer B, Gatter
KC, Harris AL (1999) bcl-2 and c-erbB-2 proteins are involved in the regu-
lation of VEGF and of thymidine phosphorylase angiogenic activity in
non-small-cell lung cancer. Clin Exp Metastasis 17: 545–554
Koukourakis MI, Giatromanolaki A, O’Byrne KJ, Whitehouse RM, Talbot
DC, Gatter KC, Harris AL (1997) Potential role of bcl-2 as a suppressor
of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer 74:
565–570
Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E,
Kakolyris S, Georgoulias V, Gatter KC, Harris AL (2000b) Vascular
endothelial growth factor/KDR activated microvessel density versus
CD31 standard microvessel density in non-small cell lung cancer. Cancer
Res 60: 3088–3095
Liao M, Wang H, Lin Z, Feng J, Zhu D (2001) Vascular endothelial growth
factor and other biological predictors related to the postoperative survival
rate on non-small cell lung cancer. Lung Cancer 33: 125–132
Lucchi M, Fontanini G, Mussi A, Vignati S, Ribechini A, Menconi GF, Bevi-
lacqua G, Angeletti CA (1997) Tumor angiogenesis and biologic markers
in resected stage I NSCLC. Eur J Cardio-thor Surg 12: 535–541
Macchiarini P, Fontanini G, Dulmet E, de Montpreville V, Chapelier AR,
Cerrina J, Le Roy Ladurie F, Dartevelle PG (1994) Angiogenesis: an indi-
cator of metastasis in non-small cell lung cancer invading the thoracic
inlet. Ann Thorac Surg 57: 1534–1539
Martin L, Green B, Renshaw C, Lowe D, Rudland P, Leinster SJ, Winstanley J
(1997) Examining the technique of angiogenesis assessment in invasive
breast cancer. Br J Cancer 76: 1046–1054
Matsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R, Tanigawa N (1998)
Tumor angiogenesis as a prognostic marker in operable non-small cell lung
cancer. Ann Thorac Surg 65: 1405–1409
Mattern J (2001) Role of angiogenesis in drug resistance. Anticancer Res
21(6B): 4265–4270
Mattern J, Kooma ¨gi R, Volm M (1995) Vascular endothelial growth factor
expression and angiogenesis in non-small cell lung carcinomas. Int J
Oncology 6: 1059–1062
Meert AP, Berghmans T, Branle F, Lemaitre F, Mascaux C, Rubesova E,
Vermylen P, Paesmans M, Sculier JP (1999) Phase II and III studies with
new drugs for non-small cell lung cancer: a systematic review of the litera-
ture with a methodology quality assessment. Anticancer Res 19: 4379–4390
Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F,
Verdebout JM, Laﬁtte JJ, Sculier JP (2001) Prophylactic cranial irradiation
in small cell lung cancer: a systematic review of the literature with meta-
analysis. BMC Cancer 1: 5
Mulrow CD (1987) The medical review article: state of the science. Ann Intern
Med 106: 485–488
O’Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward
WP, Gatter K, Harris AL (2000) Vascular endothelial growth factor, plate-
let-derived endothelial cell growth factor and angiogenesis in non-small-
cell lung cancer. Br J Cancer 82: 1427–1432
Offersen BV, Pfeiffer P, Hamilton-Dutoit S, Overgaard J (2001) Patterns of
angiogenesis in nonsmall-cell lung carcinoma. Cancer 91: 1500–1509
Ohta Y, Tomita Y, Oda M, Watanabe S, Murakami S, Watanabe Y (1999)
Tumor angiogenesis and recurrence in stage I non-small cell lung cancer.
Ann Thorac Surg 68: 1034–1038
Paesmans M, Sculier JP (1998) Les facteurs pronostiques. In: Cancers bronch-
opulmonaires, Milleron B, Depierre A (eds). pp 239–247. Arnette: Ve ￿lizy-
Villacoublay
Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to
perform meta-analyses of the published literature for survival endpoints.
Stat Med 17: 2815–2834
Pastorino U, Andreola S, Tagliabue E, Pezella F, Incarbone E, Sozzi G, Buyse
M, Menard S, Pierotti M, Rilke F (1997) Immunocytochemical markers in
stage I lung cancer: relevance to prognosis. J Clin Oncology 15: 2858–2865
Pazouki S, Chisholm DM, Adi MM, Carmichael G, Farquharson M, Ogden
GR, Schor SL, Schor AM (1997) The association between tumour progres-
sion and vascularity in the oral mucosa. J Pathol 183: 39–43
Sheng HY, Aoe M, Doihara H, Andou A, Shimizu N (2000) Prognostic value
of vascular endothelial growth factor expression in primary lung carcino-
ma. Acta Med Okayama 54: 119–126
Shibusa T, Shijubo N, Abe S (1998) Tumor angiogenesis and vascular
endothelial growth factor expression in stage I lung adenocarcinoma. Clin
Cancer Res 4: 1483–1487
Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert
AP, Vallot F, Laﬁtte JJ, Sculier JP (2001) Role of p53 as a prognostic factor
for survival in lung cancer: a systematic review of the literature with a
meta-analysis. Eur Respir J 18: 705–719
Stewart LA, Parmar MK (1993) Meta-analysis of the literature or of indivi-
dual patient data: is there a difference?. Lancet 341: 418–422
Strauss GM (1997) Prognostic markers in resectable non-small cell lung
cancer. Oncol Clin North Am 11: 409–434
Takanami I, Takeuchi K, Kodaira S (1999) Tumor-associated macrophage
inﬁltration in pulmonary adenocarcinoma: association with angiogenesis
and poor prognosis. Oncology 57: 138–142
Takanami I, Takeuchi K, Naruke M (2000) Mast cell density is associated
with angiogenesis and poor prognosis in pulmonary adenocarcinoma.
Cancer 88: 2686–2692
Takanami I, Tanaka F, Hashizume T, Kodaira S (1997) Tumor angiogenesis
in pulmonary adenocarcinomas: relationship with basic ﬁbroblast growth
factor, its receptor, and survival. Neoplasma 44: 295–298
Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T,
Muraoka R, Iki M (1996) Extent of tumor vascularization correlates with
prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res
56: 2671–2676
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella
F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantiﬁcation of
angiogenesis in solid human tumours: an international consensus on the
methodology and criteria of evaluation. Eur J Cancer 32A: 2474–2484
Vermeulen PB, Libura M, Libura J, O’Neill PJ, van Dam P, Van Marck E, Van
Oosterom AT, Dirix LY (1997) Inﬂuence of investigator experience and
microscopic ﬁeld size on microvessel density in node-negative breast carci-
noma. Breast Cancer Res Treat 42: 165–172
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S,
Gasparini G (1992) Tumor angiogenesis: a new signiﬁcant and indepen-
dent prognostic indicator in early-stage breast carcinoma. J Natl Cancer
Inst 84: 1875–1887
Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis
and metastasis–correlation in invasive breast carcinoma. N Engl J Med
324: 1–8
Yamazaki K, Abe S, Takewara H, Sukoh N, Watanabe N, Ogura S, Nakajima
I, Isobe H, Inoue K, Kawakami Y (1994) Tumor angiogenesis in human
lung adenocarcinoma. Cancer 74: 2245–2250
Yano T, Tanikawa S, Fujie T, Masutani M, Horie T (2000) Vascular endothe-
lial growth factor expression and neovascularisation in non-small cell lung
cancer. Eur J Cancer 36: 601–609
Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and
after myocardial infarction: an overview of the randomized trials. Prog
Cardiovasc Dis 27: 335–371
Microvessel density and lung cancer
A-P Meert et al
701
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 694–701